Replies to post #222170 on Biotech Values

[DewDiligence]

AZN—...they are addressing a broad range of novel targets, most of which aren't me-toos.

Sure, but how many of AZN's drug candidates for novel targets are likely to produce durable or complete responses in late-stage disease?

In oncology, the above is my definition of “innovative”; anything else I would characterize as incremental.